Profile data is unavailable for this security.
About the company
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
- Revenue in USD (TTM)296.55m
- Net income in USD-47.11m
- Incorporated2021
- Employees497.00
- LocationImmunocore Holdings PLC90 Park Drive, Milton Park, AbingdonABINGDON OX14 4RYUnited KingdomGBR
- Phone+44 123 543 8600
- Websitehttp://www.immunocore.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 599.25m | 88.59m | 980.73m | 197.00 | 15.21 | 4.18 | 4.14 | 1.64 | 2.00 | 2.00 | 13.05 | 7.27 | 0.4261 | 6.25 | 2.92 | 3,041,853.00 | 6.30 | 2.79 | 9.38 | 4.80 | 62.36 | 50.88 | 14.78 | 5.16 | 0.8832 | 3.94 | 0.7873 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 138.16m | -72.58m | 1.12bn | 154.00 | -- | 15.04 | -- | 8.12 | -0.7894 | -0.7894 | 1.48 | 0.775 | 0.7647 | 1.04 | 6.38 | 897,142.90 | -40.17 | -40.21 | -54.87 | -47.99 | 91.92 | -- | -52.53 | -374.75 | 2.60 | -6.11 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 555.46m | -8.77m | 1.17bn | 642.00 | -- | 2.90 | 22.76 | 2.11 | -0.4489 | -0.4489 | 28.67 | 20.44 | 0.5102 | 1.75 | 2.96 | 865,196.30 | -0.6514 | -2.83 | -0.7654 | -3.35 | 59.79 | 60.18 | -1.28 | -6.15 | 1.97 | 0.7018 | 0.5921 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Tilray Brands Inc | 812.04m | -212.62m | 1.18bn | 2.65k | -- | 0.3297 | -- | 1.46 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Innoviva Inc | 352.75m | 64.59m | 1.19bn | 112.00 | 27.71 | 1.78 | 11.42 | 3.38 | 0.6879 | 0.6879 | 4.78 | 10.68 | 0.2916 | 1.14 | 4.44 | 3,149,509.00 | 5.34 | 26.24 | 5.98 | 28.53 | 87.93 | -- | 18.31 | 76.84 | 1.64 | 1.93 | 0.4011 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Ocular Therapeutix Inc | 61.44m | -174.34m | 1.33bn | 267.00 | -- | 3.79 | -- | 21.62 | -1.30 | -1.30 | 0.4442 | 2.25 | 0.1883 | 2.48 | 2.28 | 230,116.10 | -53.42 | -46.70 | -59.98 | -54.18 | 90.59 | 89.36 | -283.75 | -228.65 | 12.94 | -27.52 | 0.1615 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Harrow Inc | 169.14m | -33.41m | 1.56bn | 315.00 | -- | 26.95 | -- | 9.21 | -0.9408 | -0.9408 | 4.76 | 1.63 | 0.5305 | 4.86 | 4.69 | 536,946.10 | -10.48 | -10.86 | -12.74 | -12.71 | 72.56 | 70.75 | -19.75 | -15.35 | 1.44 | -0.3529 | 0.7635 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Immunocore Holdings PLC - ADR | 296.55m | -47.11m | 1.61bn | 497.00 | -- | 4.25 | -- | 5.42 | -0.9494 | -0.9494 | 5.88 | 7.55 | 0.3593 | 0.541 | 5.68 | 596,681.90 | -5.71 | -27.55 | -7.45 | -36.82 | 99.38 | -- | -15.89 | -97.12 | 3.76 | -- | 0.5373 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Tarsus Pharmaceuticals Inc | 129.62m | -134.34m | 1.77bn | 244.00 | -- | 7.46 | -- | 13.62 | -3.76 | -3.76 | 3.58 | 6.22 | 0.4022 | 6.37 | 7.51 | 531,233.60 | -41.68 | -31.56 | -48.37 | -33.82 | 92.97 | -- | -103.64 | -242.59 | 5.38 | -- | 0.2319 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.87bn | 3.00k | -- | 1.02 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 1.90bn | 246.00 | 15.73 | 3.18 | 12.90 | 2.78 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Supernus Pharmaceuticals Inc | 651.97m | 59.71m | 1.98bn | 652.00 | 33.54 | 1.96 | 13.84 | 3.03 | 1.07 | 1.07 | 11.71 | 18.24 | 0.4962 | 0.9689 | 4.54 | 999,957.10 | 4.54 | 4.95 | 5.83 | 6.41 | 89.04 | 88.61 | 9.16 | 12.84 | 1.98 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Amphastar Pharmaceuticals Inc | 723.55m | 157.72m | 2.16bn | 1.76k | 14.82 | 2.96 | 10.21 | 2.98 | 3.01 | 3.01 | 13.79 | 15.04 | 0.4684 | 2.83 | 5.60 | 410,873.90 | 10.28 | 9.42 | 11.88 | 11.56 | 52.98 | 47.83 | 21.95 | 15.23 | 2.61 | 9.42 | 0.4506 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Ligand Pharmaceuticals Inc | 152.42m | 45.24m | 2.20bn | 58.00 | 48.03 | 2.60 | 27.27 | 14.45 | 2.43 | 2.43 | 8.25 | 44.84 | 0.1768 | 0.4689 | 4.34 | 2,627,966.00 | 5.25 | 12.32 | 5.37 | 12.99 | 93.52 | 81.65 | 29.68 | 80.32 | 11.81 | -- | 0.00003 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Data as of Nov 22 2024. Currency figures normalised to Immunocore Holdings PLC's reporting currency: US Dollar USD
64.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 30 Sep 2024 | 6.82m | 13.63% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 6.50m | 13.00% |
| RTW Investments LPas of 30 Sep 2024 | 4.87m | 9.74% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 4.60m | 9.20% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 2.47m | 4.94% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 2.16m | 4.31% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 1.52m | 3.03% |
| Armistice Capital LLCas of 30 Sep 2024 | 1.26m | 2.53% |
| Bellevue Asset Management AGas of 30 Sep 2024 | 1.21m | 2.41% |
| Tang Capital Management LLCas of 30 Sep 2024 | 1.11m | 2.21% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
